Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation

Journal of the National Cancer Institute

Volumn 88, Issue 10, 1996, Pages 680-682

  Bartsch, Detlef ^a,b   Shevlin, Douglas W ^a   Callery, Mark P ^a   Norton, Jeffrey A ^a   Wells Jr , Samuel A ^a   Goodfellow, Paul J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ARTICLE; CANCER SURVIVAL; CHRONIC PANCREATITIS; CONTROLLED STUDY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; TUMOR SUPPRESSOR GENE;

ACTUARIAL ANALYSIS; ADENOCARCINOMA; FEMALE; GENE DELETION; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MUTATION; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0029986043     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.10.680     Document Type: Article

References (23)

1. National Cancer Institute. Annual cancer statistics review 1973-1988. Bethesda (MD): DHHS Publ No. (NIH)91-2789, 1991.
2. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995;221: 59-66.
3. Lillemoe KD. Current management of pancreatic carcinoma. Ann Surg 1995;221:133-48.
4. Gudjonsson B. Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting [see comment citations in Medline]. J Am Coll Surg 1995;181:483-503.
5. Gordon TA, Cameron JL. Management of patients with carcinoma of the pancreas [editorial]. J Am Coll Surg 1995;181:558-60.
6. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991;161:120-4.
7. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-72.
8. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993;217:144-8.
9. Allison DC, Bose KK, Hruban RH, Piantadosi S, Dooley WC, Boitnott JK, et al. Pancreatic cancer cell DNA content correlates with long-term survival after pancreaticoduodenectomy. Ann Surg 1991;214:648-56.
10. Seymour AB, Hruban RH, Redston M, Caldas C, Powell SM, Kinzler KW, et al. Allelotype of pancreatic adenocarcinoma. Cancer Res 1994;54:2761-4.
11. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33.
12. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTSI) gene in pancreatic adenocarcinoma [published erratum appears in Nat Genet 1994;8:410]. Nat Genet 1994; 8:27-32.
13. Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA Jr, Goodfellow PJ. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosom Cancer 1995;14:189-95.
14. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995;333:975-7.
15. JNK4 mutations. N Engl J Med 1995;333:970-4.
16. Gruis NA, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR. CDKN2 explains pan of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 1995;5:169-77.
17. Cox DR. Regression models and life tables. J R Stat Soc 1972;34(Series B):187-220.
18. Muss HB, Thor AD, Berry DA, Kule T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer [see comment citations in Medline] [published erratum appears in N Engl J Med 1994; 331;211]. N Engl J Med 1994;330:1260-6.
19. Jessup JM, Posner M, Huberman M. Influence of multimodality therapy on the management of pancreas carcinoma. Semin Surg Oncol 1993;9:27-32.
20. Douglass HO. Current approaches to multimodality management of advanced pancreatic cancer. Hepatogastroenterology 1993; 40:433-42.
21. Taylor I. Should further studies of chemotherapy be carried out in pancreatic cancer? [editorial] Eur J Cancer 1993;29A:1076-8.
22. Moore DF Jr, Pazdur R, Abbruzzese JL, Ajani JA, Dubovsky DW, Wade JL 3d, et al. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1994;5:286-7.
23. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81:882-5.